LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

LLY

726.05

-4.28%↓

UNH

509.38

-0.31%↓

ABBV

171.37

-1.34%↓

NVO

78.73

-5.4%↓

MRK

98.01

-2.68%↓

Search

Johnson and Johnson

Cerrado

Sector Salud

146.98 -0.66

Resumen

Variación precio

24h

Actual

Mínimo

146.6

Máximo

148.28

Métricas clave

By Trading Economics

Ingresos

-2B

2.7B

Ventas

50M

23B

P/B

Media del Sector

24.52

59.526

BPA

2.42

Rentabilidad por dividendo

3.103

Margen de beneficio

11.973

EBITDA

-2.4B

5.4B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+14.94 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.10%

2.33%

Próximas Ganancias

22 ene 2025

Fecha Próximo Dividendo

4 mar 2025

Próxima Fecha de Ex Dividendo

18 feb 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.2B

349B

Apertura anterior

147.64

Cierre anterior

146.98

Noticias sobre sentimiento de mercado

By Acuity

16%

84%

24 / 392 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Johnson and Johnson Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 ene 2025, 12:11 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13 ene 2025, 11:40 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

13 ene 2025, 21:20 UTC

Adquisiciones, fusiones, absorciones

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13 ene 2025, 20:12 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13 ene 2025, 16:18 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13 ene 2025, 15:57 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13 ene 2025, 14:10 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13 ene 2025, 13:35 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 ene 2025, 12:25 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 ene 2025, 11:57 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 ene 2025, 11:56 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13 ene 2025, 11:45 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13 ene 2025, 11:43 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13 ene 2025, 11:43 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13 ene 2025, 11:42 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13 ene 2025, 11:41 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13 ene 2025, 11:40 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13 ene 2025, 11:34 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13 ene 2025, 11:32 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13 ene 2025, 11:32 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13 ene 2025, 11:31 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13 ene 2025, 11:31 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13 ene 2025, 11:30 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13 ene 2025, 10:55 UTC

Adquisiciones, fusiones, absorciones

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13 ene 2025, 10:41 UTC

Adquisiciones, fusiones, absorciones

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

2 ene 2025, 14:00 UTC

Principales Noticias

Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops -- IBD

13 dic 2024, 20:55 UTC

Principales Noticias

J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds -- Update

13 dic 2024, 20:31 UTC

Principales Noticias

J&J Accuses Big Health Insurer of Helping Drain Its Drug Copay Funds -- WSJ

10 dic 2024, 07:05 UTC

Charlas de Mercado

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

9 dic 2024, 02:14 UTC

Principales Noticias

Apple Tops the List of Best-Managed Companies of 2024 -- Journal Report -2-

Comparación entre iguales

Cambio de precio

Johnson and Johnson Esperado

Precio Objetivo

By TipRanks

14.94% repunte

Estimación a 12 meses

Media 169 USD  14.94%

Máximo 185 USD

Mínimo 160 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Johnson and Johnson Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

4

Comprar

7

Mantener

0

Vender

Puntuación técnica

By Trading Central

144.19 / 147.77Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

24 / 392 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.